8 / 9
Volume 7
Journal of Metabolic Syndrome
ISSN : 2167-0943
Metabolic Syndrome 2018 | Endoscopy 2018
June 28-29, 2018
Page 34
conference
series
.com
ENDOCRINOLOGY AND METABOLIC SYNDROME
&
ABDOMINAL IMAGING AND ENDOSCOPY
June 28-29, 2018 Amsterdam, Netherlands
12
th
International Conference on
3
rd
International Conference on
JOINT EVENT
Renming Hu, J Metabolic Synd 2018, Volume 7
DOI: 10.4172/2167-0943-C1-007
Anti-inflammatory treatment of diabetes and metabolic syndrome or metabolic inflammatory
syndrome
C
hanges in modern habits and environment produce metabolic products, including FFA and LPS, which polarize
macrophages and induce chronic low grade inflammation, which damage tissues and organs and lead to metabolic
diseases. Polarized macrophages not only participate in the pathophysiological process of AS, but macrophages can also invade
the islets, adipocytes and liver tissues and damage these tissues and participate in the pathophysiological process of type 2
diabetes (T2DM), obesity and nonalcoholic fatty liver (NAFLD). AS, T2DM, NAFLD and obesity are closely related to chronic
low grade inflammation and often accumulate, exist, or concurrency. Therefore, researchers compared AS, T2DM, NAFLD
and obesity to 4 melons on a vine (chronic low inflammation), and proposed the concept and construction of metabolic
inflammatory syndrome (Metabolic Inflammatory Syndrome, MIS). MIS is diagnosed as having 2 or more than 4 metabolic
diseases above 4 in addition to the endocrine diseases of the known cause such as Cushing syndrome, Acromegaly and
primary hypothyroidism.The concept of MIS is in line with the theory of system biology and integrated medicine, which is
beneficial to the interdisciplinary, basic and clinical combination, and to create a new method for the effective prevention and
treatment of metabolic diseases with the same treatment of different diseases and the same treatment with different diseases.
MIS is the development of metabolic syndrome (MS). As early as the 60-70 years of twentieth Century, researchers have
found that obesity, hypertension, dyslipidemia, and diabetes are more likely to be associated with cardiovascular disease, and
the combination of these metabolic risk factors is called metabolic syndrome. In 1998, WHO expert group formally named
this and put forward the diagnostic standard. Subsequently, various organizations discussed and revised their components.
Microalbuminuria, impaired fasting blood glucose, or abnormality of glucose tolerance are still in the first 4 items, and the
disputed risk factors include chronic low grade of inflammation (such as CRP, PAI-1), hyperuricemia, nonalcoholic fatty liver,
and so on. According to the diagnostic criteria of MS, Cushing syndrome, Acromegaly and primary hypothyroidism and other
diseases is also consistent with the diagnosis of MS, suggesting that MS concepts are to be discussed. The concept of MIS can
better induce the metabolic diseases caused by chronic low grade inflammation. AS has become a major risk factor for human
health. Therefore, screening and early diagnosis of AS is very important. The concept and diagnosis of MIS will encourage
and promote T2DM, NAFLD and obese people to screen AS. Therefore, the concept of MIS is helpful for early diagnosis and
prevention of AS.
Biography
Renming Hu got the M.D and PhD from Shanghai second Medical University in 1973 and 1988. He worked the department of Endocrinology affiliated to University
of Chicago during 1988-1990. He finished post doctor training in University of California during 1990-1993 and worked Department of Endocrinology at UCI as an
assistant researcher from 1994 to 1996. He worked in Rui Jin Hospital affiliated to Shanghai Second Medical University during 1996-2002 as vice director of Institute of
Endocrinogy of Shanghai and vice director of Department of Endocrinogy. He was promoted as a professor in 1999. He was director of Department of Endocrinology of
Huashan Hospital affiliated to Fudan University and The Institute of Endocrinology and Diabetology at Fudan University during 2002-2010. Now he is director of Institute of
Endocrinology and Diabetology at Fudan University and director of Department of Endocrinology of Jinshan Hospital affiliated to Fudan Univesity.
renminghu@fudan.edu.cnRenming Hu
Fudan University, China